Should You Invest In AbbVie Inc?

AbbVie Inc. is a global biopharmaceutical company that researches, develops, manufactures, and commercialises medicines and therapies. Incorporated in 2012, it has its headquarters in North Chicago, Illinois. AbbVie primarily offers products that address issues in the immunology, oncology, neuroscience, women's health, eye care, and aesthetics areas. The company's immunology products include Humira, Rinvoq, and Skyrizi; products in the oncology field include Venclexta and Imbruvica; aesthetics products include the Juvederm collection and Botox Cosmetic. AbbVie also produces Restasis, Alphagam, and Lumigan for eye care and Orilissa and Lo Loestrin for women's health, as well as Botox Therapeutic, Vraylar, Duodopa, Duopa, and Ubrelvy for the neuroscience field. AbbVie sells its products directly to distributors, wholesalers, healthcare facilities, government agencies, and independent retailers. Listed on the NYSE, AbbVie stock is available under the ticker ABBV. As of December 2021, AbbVie has approximately 48,000 employees working across more than 70 countries. On 10 May 2021, the company announced that its Allergan Aesthetics subsidiary would acquire Soliton, the maker of RESONIC, an FDA-approved Rapid Acoustic Pulse device. This acquisition expands Allergan Aesthetic's body contouring treatment portfolio. The deal was reported to be worth approximately $550m. Track ABBV share price movements by adding it to your eToro watchlist.